Condition

Metastatic Adult Soft Tissue Sarcoma (4)

Drug Toxicity (1)

Drug Use (1)

GIST (1)

Maximum Tolerated Dose (1)

Recurrent Adult Soft Tissue Sarcoma (1)

Overall Status

Completed (2)

Active, not recruiting (1)

Recruiting (1)

Phase

phase 2 (3)

phase 1/phase 2 (1)

Sponsor

AGC Biologics S.p.A. (1)

AIO-Studien-gGmbH (1)

Grupo Espanol de Investigacion en Sarcomas (1)

University Medicine Greifswald (1)

Collaborator

AstraZeneca (1)

Bristol-Myers Squibb (1)

Institut fur Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest (1)

PharmaMar (1)

Intervention

doxorubicin (2)

durvalumab and tremelimumab (1)

high-dose ngr-htnf (1)

imatinib (1)

low-dose ngr-htnf (1)

nivolumab (1)

selinexor (1)

trabectedin (1)

Study Documents

Intervention Type

drug (4)

biological (1)

Funder Type

Other (3)

Industry (1)

Study Type

Interventional (4)

metastatic adult soft tissue sarcoma

Showing 1 - 4 of 4

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Metastatic Adult Soft Tissue Sarcoma, Recurrent Adult Soft Tissue Sarcoma Trial in Hannover (Durvalumab and Tremelimumab,

Completed

Metastatic Adult Soft Tissue Sarcoma
Recurrent Adult Soft Tissue Sarcoma

Durvalumab and Tremelimumab
Doxorubicin

Hannover, Germany

Medizinische Hochschule Hannover

Jan 18, 2023

Metastatic Adult Soft Tissue Sarcoma Trial in Germany (Trabectedin, Nivolumab)

Active, not recruiting

Metastatic Adult Soft Tissue Sarcoma

Bad Saarow, Germany
+8 more

Feb 19, 2021

Maximum Tolerated Dose, GIST, Metastatic Adult Soft Tissue Sarcoma Trial in Spain (Selinexor, Imatinib)

Recruiting

Maximum Tolerated Dose
+4 more

Sevilla, Andalucia, Spain
+5 more

Oct 21, 2020

Metastatic Adult Soft Tissue Sarcoma Trial in France, Italy, United Kingdom (low-dose NGR-hTNF, high-dose NGR-hTNF, Doxorubicin)

Completed

Metastatic Adult Soft Tissue Sarcoma

low-dose NGR-hTNF
+2 more

Lyon, France
+6 more

Aug 27, 2018